Sarah Collins
Disclosure: I am in full compliance with all ethics and other policies for Market Realist research analysts. I am not invested in securities that I cover on Market Realist.
More From Sarah Collins
What Lies Ahead for Thermo Fisher’s Life Sciences Solutions Business?
TMO’s Life Sciences Solutions segment registered revenue growth of around 11% in 1Q16. The company reported strong growth in biosciences.
The Impact of Dispensing Business Changes on BD’s Revenue
US dispensing business headwinds BD (BDX) has introduced some changes to its US dispensing business as part of its efforts to transform its medication management solutions. The initiative has impacted the company’s performance due to related accounting changes. For details, read Headwind for Becton Dickinson: US Dispensing Business. These changes had a higher-than-expected impact in 3Q17 and 4Q17, and […]
Johnson & Johnson’s Latest Dividend Payment: Is It Important?
Johnson & Johnson (JNJ) announced a quarterly cash dividend of $0.80 per share on July 18, 2016, payable on September 6, 2016. This is the same as the previous quarter.
Analysts Raise Target Prices for TEVA after Its Q2 2018 Results
Teva Pharmaceutical Industries (TEVA) reported its Q2 2018 earnings results yesterday and updated its fiscal 2018 guidance.
Analyst Recommendations for Thermo Fisher Scientific
Based on recommendations by 21 broker firms surveyed by Bloomberg, the consensus rating for Thermo Fisher Scientific was “buy” from 19 of the firms and “hold” from two of the firms.
How BD Is Accelerating Its Safety Revenues after Flat Growth in 3Q17
Becton Dickinson (BDX), or BD, acquired the global safety products portfolio through the acquisition of CareFusion in 2015.
Mylan Stock Falls on Analyst Downgrade, Trades at 52-Week Low
Today, Morgan Stanley downgraded Mylan (MYL) from “overweight” to “equal weight.” The firm also cut its target price for MYL stock from $46 to $36.
Could Pfizer and P&G agree on a Consumer Health Business Deal?
Pfizer (PFE) has been looking to sell its consumer health business since October 2017.
What’s Nektar Therapeutics’ Guidance for Fiscal 2018?
For full fiscal 2018, the company expects to register R&D (research and development) expenses of $400 million to $425 million.
What to Expect from St. Jude Medical’s Earnings in 2Q16
In 1Q16, St. Jude Medical exceeded analysts’ EPS (earnings per share) estimate of $0.89 as well as the revenue estimate of ~$1.4 billion.
What Pushed Teva’s Earnings Above Analysts’ Estimate
Teva Pharmaceutical Industries (TEVA) reported its Q2 2018 earnings results yesterday, missing analysts’ sales estimates.
Abbott Received CE Mark for a Test to Predict Heart Attacks
Abbott Laboratories (ABT) announced that it had received a CE mark for its high sensitivity troponin-I blood test on September 26.
Weighing in with Boston Scientific’s 4Q15 Revenues
Boston Scientific reported its 4Q15 earnings on February 4 and registered adjusted EPS of $0.26 in 4Q15, which represents 18% YoY growth.
How Long Will Stryker Stock Sustain Its Bullish Trend?
Stryker (SYK) closed at $145.4 on July 18, 2017. It has a 50-day moving average of $141.8 and a 200-day moving average of $132.6.
Becton, Dickinson and Company’s 4Q16 Earnings Estimates
Wall Street projected a rise in Becton, Dickinson and Company’s (BDX) adjusted net profit margins. The margins are expected to come in at ~$453 million.
Align Technology Reported a 52-Week High on May 29
Align Technology (ALGN) hosted its 2018 Investor Day on May 23. On the day, the company provided a variety of updates.
Most Analysts Rate Boston Scientific a ‘Buy’
Based on the recommendations of 27 brokerage firms in a Bloomberg survey, about 78% gave Boston Scientific a consensus rating of “buy.”
How Wall Street Reacted to the Delay in BSX’s Lotus Edge Launch
Boston Scientific (BSX) announced the delay in the commercialization timelines of BSX’s Lotus devices in Europe and the US on November 28, 2017.
Varian Medical Systems’ Oncology Devices Are Key to Sales Growth
Varian Medical Systems commands the majority share of the oncology device market in the United States.
What Analysts Predict for Thermo Fisher’s 2Q17 Revenues
Wall Street estimates that Thermo Fisher Scientific’s (TMO) 2Q17 revenue will come in at ~$4.9 billion, a rise of ~8.5% on a YoY (year-over-year) basis.
Here Are the Latest Analyst Recommendations for Biogen
The consensus 12-month target price for Biogen is $342.7, an ~11.4% return potential.
How Does UNH’s Valuation Look in October?
UnitedHealth Group is a leading managed healthcare firm in the United States.
Analysts Recommend Boston Scientific as a Strong ‘Buy’
Boston Scientific will release its 1Q16 earnings results on April 27. In a survey of 28 brokerage firms, about 78.6% of the firms rated Boston Scientific as a “buy.”
What’s Expected of Baxter International in Fiscal 2017?
Baxter International (BAX) has updated its sales guidance growth from 2.0%–3.0% to approximately 4.0% on a constant currency basis.
Will Medtronic Maintain Its Revenue Growth Momentum in Fiscal 1Q18?
In fiscal 1Q18, Wall Street analysts expect Medtronic’s (MDT) revenue to be ~$7.45 billion, which represents a rise of ~4% in comparison to its fiscal 1Q17 revenue of $7.17 billion.
Could Johnson & Johnson’s Earnings Grow in 3Q16?
Analysts’ estimates Johnson & Johnson (JNJ) accounts for ~6.3% of the total holdings of the iShares Core High Dividend ETF (HDV). The company has managed to exceed analysts’ earnings estimates for the last several quarters. The movement in a company’s share price is generally impacted by the deviation of its actual results from analysts’ estimates. Usually, a stock’s […]
Trial Progression of St. Jude Medical’s Stroke Prevention Device
On September 1, St. Jude Medical (STJ) launched its AMPLATZER Amulet IDE trial that will expand the device’s access to atrial fibrillation patients.
Boston Scientific’s 1Q18 Revenues: What to Expect
On April 25, Boston Scientific (BSX) plans to announce its 1Q18 earnings results—the quarter that ended on March 31.
Why Analysts Expect Teva’s Revenues to Fall in the Second Quarter
For the second quarter of fiscal 2018, Wall Street expects Teva Pharmaceutical Industries to register a YoY sales decline of 16.6%.
Boston Scientific’s Q2 2018 Adjusted EPS Exceed Guidance
In the second quarter, Boston Scientific’s adjusted EPS grew 28% YoY (year-over-year) to $0.41, exceeding its guidance of $0.33–$0.35.
Mylan Has a Strong Balance Sheet despite Weak Q2 Performance
On June 30, Mylan’s debt-to-adjusted EBITDA multiple was 3.9x.
Analysts Expect Medtronic’s Revenue to Rise 4% in Fiscal 4Q17
Wall Street analysts expect Medtronic’s (MDT) revenue to be ~$7.9 billion in fiscal 4Q17, a rise of ~4% compared to its fiscal 4Q16 revenue of $7.6 billion.
What Drove Edwards Lifesciences’ 1Q18 Earnings?
In 1Q18, Edwards Lifesciences (EW) registered sales of $551.6 million from its THVT (transcatheter heart valve therapy) segment.
Teva Stock Has Risen Significantly since November Lows: What’s Next?
On January 5, 2018, Teva Pharmaceuticals (TEVA) closed at $19.2 per share, which was ~77% higher than its 52-week low of $10.8 reported on November 2, 2017.
Thermo Fisher Scientific: What’s Been Driving Growth?
In this series, we discuss the major drivers of Thermo Fisher Scientific’s valuation, stock performance. and growth fundamentals.
Analyst Recommendations for Stryker: Most Say ‘Buy’
In a Reuters survey of 27 brokerage companies, about 63.0% of analysts have rated Stryker a “buy,” and 26.0% have rated it a “hold.”
What Analysts Are Saying about Becton Dickinson Now
Analysts estimate that Becton Dickinson has a potential to return ~6.4% over the next 12 months. The 12-month target price for BDX is $163.10 per share.
What to Expect from Edwards Lifesciences’ Fiscal 3Q17 Results
Edwards Lifesciences (EW) has scheduled its 3Q17 earnings release for October 24, 2017. This leading player in the artificial heart valves market has been gaining momentum and trading near its 52-week high.
Stryker: Analysts’ Recommendations before Its 3Q17 Earnings
Stryker (SYK), the second-largest orthopedic device developer, is set to announce its 3Q17 earnings results on October 26, 2017.
A Look at Abbott Laboratories’ Valuation Multiples
May 3, Abbott Laboratories had a 12-month forward PEG ratio of ~1.5x, compared to the ~1.6x PEG multiple recorded in April.
How Has Medtronic’s Stock Performed Recently?
Medtronic (MDT) was trading at $80.3 on November 15, 2016. It had a 50-day moving average of $83.7 and a 200-day moving average of $84.8.
Recent Developments with Roche’s Lung Cancer Drug Tecentriq
On April 9, 2018, Roche (RHHBY) said it has received approval for Tecentriq from NICE for the treatment of the most common form of lung cancer.
Mylan’s EpiPen Supply Shortages Continue: What to Expect Ahead
During its second-quarter earnings release on August 8, Mylan provided an update on its EpiPen supply shortages.
What Wall Street Analysts Recommend for Dentsply Sirona
Dentsply Sirona (XRAY), one of the leading dental technology providers in the United States, recently outlined a turnaround plan to recover from the company’s disappointing performance in recent years.
A Look at Boston Scientific’s Valuation Multiples in September
On September 14, Boston Scientific (BSX) was trading at a forward price-to-earnings ratio of 24.4x, compared to the industry’s average PE ratio of 22.4x.
JNJ’s Medical Devices Growth Plans amid Changing Market Dynamics
Johnson & Johnson (JNJ) has been working on changing its business model.
Johnson & Johnson Is Reinventing Its Oral Care Franchise
Johnson & Johnson’s (JNJ) oral care business registered an operational sales decline of 3.2% in fiscal 2017.
Wilson Disease: A Market Opportunity for Alexion
Wilson Therapeutics is developing a drug to treat Wilson disease. Wilson disease is a rare genetic disorder that’s potentially life-threatening.
How Hologic’s Valuation Stacks Up with Peers
The company has delivered a robust financial performance in recent quarters. However, the stock has been on a bearish trend during the recent period.
Wall Street Analysts See Upside Potential of 3.9% in TEVA
Teva is gradually recovering from the lows it witnessed in late 2017 due to generics competition, pricing pressure, and declining Copaxone sales.
Align Technology: Analysts Raise Their Target Prices
On May 25, Berenberg increased its 12-month target price on Align Technology (ALGN) from $312 to $340.
What’s Driving BSX’s Cardiac Rhythm Management Business
In Q2 2018, Boston Scientific’s (BSX) CRM (cardiac rhythm management) sales rose ~3% YoY (year-over-year) to $494 million.
Acceleron Pharmaceuticals and Celgene Rise on Meeting Study Goals
Today, Celgene (CELG) and Acceleron Therapeutics (XLRN) stocks are trending higher on the news of their Phase 3 clinical trial for luspatercept meeting its goal.
Jefferies Raises Target Price for BSX, Stock Rises
Today, Jefferies raised its target price for Boston Scientific (BSX) stock from $42 to $45. Let’s take a closer look.
ALGN Stock Surpasses the S&P 500 Index’s Year-to-Date Gain
On September 28, Align Technology (ALGN) posted an ~74% increase year-to-date. In the same period, the S&P 500 Index has returned ~9%.
Tandem Diabetes Care Rallies on FDA Approval of Insulin Pump
Today, Tandem Diabetes Care (TNDM) opened~16.2% higher than yesterday’s closing price of $20.31, triggered by the news of FDA approval of its t:slim X2 insulin pump with Basal IQ technology.
ABT’s Medical Devices Business: A Key Growth Driver
In 1Q18, ABT registered revenues of $7.4 billion, which represents year-over-year growth of ~16.7%.
Analysts Expect a Fall in Dentsply Sirona’s Adjusted Earnings
Dentsply Sirona accounts for ~0.29% of the total holdings of the Vanguard Mid-Cap ETF. It’s set to release its 1Q18 results on May 7.
Medtronic’s Revenue Is Estimated to Rise in Fiscal 2Q17
On November 22, 2016, Medtronic (MDT) will announce its fiscal 2Q17 earnings for the period that ended on October 31, 2016.
Zimmer Biomet Stock Regains Momentum: What’s Driving Growth?
Ximmer Biomet (ZBH) has risen 2.1% since its 1Q17 earnings release on April 27, 2017. The results exceeded analysts’ estimates, but ZBH lowered its 2017 guidance.
A Look at Teva Pharmaceutical’s Valuation Multiples in June
On June 13, Teva Pharmaceutical Industries (TEVA) was trading at a forward PE (price-to-earnings) ratio of 8.8x, compared to the industry average PE of 12.3x.
FDA Approves Medtronic’s Enlite Sensor for iPro2 CGM System
Medtronic (MDT) is consistently working on expanding access to and improving diabetes management via new and enhanced products and services.
Teva Stock Continues to Trend Higher on Positive News
Teva Pharmaceutical Industries (TEVA) has risen ~9% over the last five days.
Boston Scientific Stock Up Today on the Acquisition of Veniti
Boston Scientific (BSX) announced the acquisition of Veniti for $108.0 million. BSX already owns a 25% stake in Veniti.
Abbott Laboratories Traded at a 52-Week High after Posting Strong 4Q17 Results
On January 29, 2018, Abbott Laboratories (ABT) closed trading at $63.31 per share. The company reported its 52-week high of $64.60 on January 25.
Why Incyte Stock Fell ~9% on April 24
On April 24, Incyte (INCY) stock fell ~9% on news regarding its drug Baricitinib, which is under FDA review.
Mylan Launches First Adcirca Generic, Stock Moves Up
Mylan Pharmaceuticals (MYL) announced the launch of tadalafil tablets USP (20 mg) in the United States.
UnitedHealth Group Goes Ex-Dividend Today
UnitedHealth Group (UNH) has announced that its board of directors has authorized a cash dividend of $0.90 per share.
A Look at Nektar’s Recent Collaboration with Isoplexis
On June 26, Isoplexis, a privately held life sciences company, and Nektar Therapeutics, announced a collaboration focused on the functional impact of Nektar’s NKTR-214 in the clinical setting at the single-cell level.
Tandem Diabetes Care’s International Expansion Strategy
Tandem Diabetes Care (TNDM) is slated to begin its international expansion later this year to capture opportunities arising after Johnson & Johnson’s (JNJ) exit from the insulin pump market, which was announced in October 2017.
Edwards Lifesciences and Boston Scientific: Patent Dispute Update
Edwards Lifesciences’ and Boston Scientific’s patent dispute On March 23, 2018, Edwards Lifesciences (EW) announced that it won its dispute with Boston Scientific (BSX) over US Patent 8992608. The USPTO (US Patent and Trademark Office) decided in favor of Edwards in an inter partes review filed by Boston Scientific against Edwards for its TAVR (transcatheter aortic valve replacement) technology, finding […]
JNJ’s Consumer Business Expected to Be Driven by Innovation
Johnson & Johnson started shipments of its revamped baby care line in July, which is expected to register improved performance in the third quarter.
Discussing Analysts’ Latest Recommendations on VAR Stock
Varian Medical Systems (VAR) is a better-aligned, leaner business with a strong market position after the spin-off of Varex Imaging (VREX) in January 2017.
Varian’s Halcyon Reaches Milestone Achievements
Halcyon is the company’s new treatment platform for cancer patients that visually enhances and simplifies image-guided radiotherapy treatments (or IMRT).
Sanofi Focuses on Integrating Recently Acquired Ablynx
On January 29, Sanofi announced its acquisition of Ablynx for $4.8 billion, and it announced the completion of the acquisition on June 19.
Analysts Raise Target Prices on ABT ahead of Q3 Earnings
Abbott Laboratories (ABT) is slated to announce its third-quarter earnings results on October 17.
Teva’s Fremanezumab Gets September Action Date from FDA
On May 23, 2018, Teva (TEVA) announced that the FDA’s Prescription Drug User Fee Act action date is set for September 16.
Berkshire Hathaway Increased Its Stake in Teva Again
Teva stock has gained ~27.0% year-to-date on the back of the positive news that included product launches and study data.
Why Alnylam Pharmaceuticals Stock Rose ~16% Yesterday
Yesterday, Alnylam Pharmaceuticals (ALNY) closed the day ~16.3% higher than the previous day’s closing price.
What Really Disrupted Medtronic’s Diabetes Segment Sales in Fiscal 2Q17?
Of Medtronic’s ~$7.3 billion in worldwide revenues in fiscal 1Q17, ~$0.46 billion came from its Diabetes segment, representing ~6% of the company total.
Biogen: Analysts’ Views before Its Second-Quarter Results
On July 24, Biogen (BIIB) is scheduled to release its second-quarter earnings results. Analysts expect Biogen to report sales of $3.3 billion.
Why Heron Therapeutics Rose 33% in Pre-Market Trading Today
Heron Therapeutics (HRTX) stock surged after the company announced it had received breakthrough designation from the FDA for its postoperative pain management drug, HTX-011.
Sangamo Therapeutics Rose despite Q2 Sales Miss, Higher Losses
Sangamo Therapeutics (SGMO) stock rose ~16% in afternoon trading. SGMO released its Q2 earnings results on August 8 after the market closed.
Analysts’ Latest Recommendations for Baxter: Mostly ‘Holds’
Let’s look at Wall Street analysts’ recommendations and target prices for Baxter International (BAX) over the next 12 months.
Why Analysts Raised Their Target Prices on WMGI Stock in August
On August 31, Wright Medical Group had a consensus 12-month target price of $32.07 per share.
Gilead Sciences Focuses on a Strong Inorganic Growth Strategy
Gilead Sciences witnessed falling revenues in the past few quarters. Its growth is expected to be revived through new products and mergers and acquisitions.
UNH’s Stock Price Performance in June
On June 28, UnitedHealth Group (UNH) ended the trading day at $244.90, ~4.6% lower than its 52-week low of $183.86 reached on July 18, 2017.
How Will the Lotus Recall Affect BSX’s 2017 Performance?
Boston Scientific has begun implementing the necessary fixes for its Lotus Valve system, and it expects to relaunch the product in the Europe and other international markets in 4Q17.
MYL Stock Down ~3% since Its Q2 2018 Results on August 8
The closing price for Mylan (MYL) stock on August 10 was $37.21, and its market capitalization stood at $19.2 billion.
Mylan’s Morgantown Restructuring and Remediation Program
Mylan’s Morgantown restructuring and remediation program comprises discontinuing certain products on the basis of profitability, market competition, and pricing dynamics.
Investor Insights: Teva Pharmaceutical’s Valuation Multiples
On October 11, Teva Pharmaceutical Industries (TEVA) was trading at a forward PE (price-to-earnings) ratio of 7.5x compared to the industry average PE of 11.5x.
How Tax Reform Affected Medtronic’s 3Q18 Performance
Tax reform and Medtronic’s 3Q18 results The Tax Cuts and Jobs Act was enacted in the United States in December 2017, and it seems to have affected healthcare companies’ balance sheets significantly in recently reported quarters. Most medical technology companies, including Abbott Laboratories (ABT), Boston Scientific (BSX), and Thermo Fisher Scientific (TMO), reported one-time balance sheet items related to […]
How J&J Has Expanded Its Orthopedics Business
Johnson & Johnson is focused on strengthening its medical device technologies business.
How Sanofi’s Valuation Compares
Sanofi (SNY) has recently been working on expanding its product portfolio in areas with potential growth and strong margins.
What Zimmer Biomet’s Progress II Study Success Could Mean
On December 22, 2017, Zimmer Biomet Holdings (ZBH) published the results of its Progress II trial, and the results were positive.
A Look at Hologic Stock’s Recent Performance
Currently, HOLX stock is trading lower than its 50-day moving average of $39.80 but higher than its 200-day moving average of $39.16.
Diabetes Management Breakthrough: Medtronic’s MiniMed 670G
On June 7, 2017, Medtronic (MDT) announced the launch of MiniMed 670G—the world’s first HCL (hybrid closed loop) insulin delivery system.
Sanofi, Adaptive Biotechnologies Plan Multiple Myeloma Trials
On May 29, Adaptive Technologies and Sanofi (SNY) formed a collaboration for a multiple myeloma trial.
Why Senseonics Holdings Is Up ~5.6% Today
Today, Senseonics Holdings (SENS) is trading higher than yesterday’s close of $4.43 per share. The stock was up ~5% in premarket trading and is trending higher since then.
Analysts’ Views on Tandem Diabetes Care after Its FDA Approval
After the market closed on June 21, Tandem Diabetes Care (TNDM) announced the FDA’s approval of its t:slim X2 insulin pump.
